TLDR
- Mangoceuticals (MGRX) stock surged ~70% in premarket trading Friday
- Injectable TRT program sales up 336% month-over-month since mid-December launch
- Customer acquisition costs cut by 54%
- The $99/month all-inclusive program covers doctor visits, labs, and medication
Mangoceuticals (MGRX) shot up roughly 70% in premarket trading Friday after the Dallas-based telehealth company reported explosive early results from its $99-per-month injectable testosterone replacement therapy program.
The program launched in mid-December and has already posted 336% month-over-month sales growth. That kind of early traction is hard to ignore, even for skeptics.
The all-inclusive plan covers doctor visits, medical consultations, lab work, and prescribed medication for a flat $99 monthly fee. MangoRx says every product is prescribed through licensed healthcare providers following medical evaluations and lab testing.
Alongside the sales surge, the company said it cut customer acquisition costs by 54%. Lower costs and higher sales at the same time is the combination every small-cap growth company is chasing.
CEO and founder Jacob Cohen called the early demand “encouraging,” saying the results demonstrate the value of the company’s approach to men’s hormone health.
The company also said TRT is now its primary growth focus going forward. It plans to invest in both injectable and oral formulations, including PRIME by MangoRx, powered by Kyzatrex.
Market Context
The global TRT market is currently valued at roughly $2.1 to $2.2 billion in 2025, with a projected compound annual growth rate of around 3.9%.
MangoRx operates under both the MangoRx and PeachesRx brands as a telehealth platform focused on health and wellness products.
Trading Volume and Price History
Trading volume told its own story Friday. More than 122 million MGRX shares changed hands, compared to a three-month daily average of just 208,000 units.
That’s roughly 586 times normal volume — a level that signals retail-driven momentum more than institutional conviction.
Before Friday’s move, MGRX was down 51.88% year-to-date and had fallen 91.78% over the prior 12 months. Context matters here.
Wall Street analyst coverage of the stock remains thin.
The company reported 336% month-over-month TRT program growth and a 54% reduction in customer acquisition costs since the mid-December launch.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
